Tools

LEADER 03464cam a22005897a 4500

001 ssj0000096382;

003 WaSeSS;

005 20220112082112.0;

006 m d ;

007 cr n ;

008 100525s2009 dcua sb 100 0deng d;

010 a| 2010279537;

016 7 a| 1015183732| DNLM;

020 a| 9780309131247 (pbk.);

020 a| 0309131243 (pbk.);

035 a| (WaSeSS)ssj0000096382;

042 a| nlmcopyca| lccopycat;

049 a| EREEa| NEHH;

050 00 a| R853.B54b| I58 2009;

060 00 a| 2009 K-807;

060 10 a| QV 744b| I59c 2009;

082 04 a| 616.0752| 22;

110 2 a| Institute of Medicine (U.S.).b| Forum on Drug Discovery, Development, and Translation.=| ^A1035701;

245 10 a| Accelerating the development of biomarkers for drug safetyh| [electronic resource] :b| workshop summary /c| Steve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.;

260 a| Washington, D.C. :b| National Academies Press,;

300 a| xv, 83 p. :b| ill. ;c| 23 cm.;

500 a| Errata sheet inserted.;

504 a| Includes bibliographical references.;

505 0 a| Overview Of key issues -- Cardiac safety biomarkers -- Assessing and predicting kidney safety -- Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials -- Future considerations.;

506 a| Available only to authorized users.;

520 a| "Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held 'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website.;

530 a| Also available online.;

538 a| Mode of access: World Wide Web;

650 0 a| Biochemical markersv| Congresses.=| ^A1235879;

650 0 a| Drugsx| Safety measuresv| Congresses.=| ^A640;

650 0 a| Drugsx| Testingv| Congresses.=| ^A1195412;

650 12 a| Biomarkers, Pharmacologicalv| Congresses.=| ^A1205468;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Olson, Steve,d| 1956-=| ^A148058;

700 1 a| Robinson, Sally.=| ^A700689;

700 1 a| Giffin, Robert B.=| ^A1332502;

856 40 z| Full text available from Ebook Central - Academic Completeu| https://ebookcentral.proquest.com/lib/eastcarolina/detail.action?docID=3378514;

947 a| (OCoLC)ocn431872188;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 3957730;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 3957730-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 1/1/2016x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 3957730-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 1/1/2016x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 3957730-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 1/1/2016x| EBOOKz| JERESOURCE;

Accelerating the development of biomarkers for drug safety workshop summary / Steve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Author/creator	Institute of Medicine (U.S.).
Other author	Olson, Steve, 1956-
Other author	Robinson, Sally.
Other author	Giffin, Robert B.
Format	Electronic
Publication Info	Washington, D.C. : National Academies Press,
Description	xv, 83 p. : ill. ; 23 cm.
Supplemental Content	Full text available from Ebook Central - Academic Complete
Subjects	Biochemical markers--Congresses. Drugs--Safety measures. --Congresses. Drugs--Testing. --Congresses. Biomarkers, Pharmacological--Congresses.

Contents	Overview Of key issues -- Cardiac safety biomarkers -- Assessing and predicting kidney safety -- Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials -- Future considerations.
Abstract	"Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held 'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website.
General note	Errata sheet inserted.
Bibliography note	Includes bibliographical references.
Access restriction	Available only to authorized users.
Other forms	Also available online.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2010279537
ISBN	9780309131247 (pbk.)
ISBN	0309131243 (pbk.)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Accelerating the development of biomarkers for drug safety workshop summary / Steve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Click here for more information about this title

Availability